



Cosentyx® (secukinumab) – New Indications

- On January 15, 2016, [Novartis announced](#) the [FDA approval](#) of [Cosentyx \(secukinumab\)](#) for the treatment of two new indications, adult patients with active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS).
 - Cosentyx is also FDA approved for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
- In the U.S., it is estimated that up to 0.5% and 1% of the population have AS and PsA, respectively. These conditions may lead to irreversible damage to the spine and joints, causing life-long pain and disability.
- Secukinumab is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A cytokine, a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Secukinumab inhibits the release of pro-inflammatory cytokines and chemokines.
- Cosentyx's new indications are based on the efficacy and safety of four placebo-controlled clinical trials of over 1,500 adult patients with AS or PsA. The primary endpoint was at least a 20% improvement in the Assessment of Spondyloarthritis International Society criteria (ASAS 20) at 16 weeks, and a 20% reduction in the American College of Rheumatology (ACR 20) response criteria at 24 weeks.
 - In all four trials, significantly more Cosentyx-treated patients met the primary endpoints vs. placebo.
- The recommended dose of Cosentyx for PsA in patients with coexistent plaque psoriasis is the same recommended dose for the treatment of plaque psoriasis: 300 mg by subcutaneous injection at weeks 0, 1, 2, 3 and 4 followed by 300 mg every 4 weeks. For some patients, a dose of 150 mg may be acceptable.
- For other PsA patients and for the treatment of AS, Cosentyx may be administered with or without a loading dose:
 - With a loading dose: 150 mg at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter
 - Without a loading dose: 150 mg every 4 weeks
 - If a patient continues to have active PsA, a dose of 300 mg may be considered



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.